Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab and Lenalidomide in Residual Large B Cell Lymphoma After Axi-cel
NCT06760156Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tafasitamab, lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Moffitt Cancer Center. Started Mar 2025; status: recruiting.
02
Drugs
tafasitamablenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06760156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06760156.